Suositeltu Epclusa-annos aikuisille on yksi 400 mg/100 mg tabletti kerran vuorokaudessa 12 viikon ajan. Randomization was stratified by HCV genotype (1, 2, 4, 6, and indeterminate) and the presence or absence of compensated cirrhosis.Demographics and baseline characteristics were balanced between the Epclusa and placebo group. Not only does coffee consumption slow liver disease progression and increase the chances of success while undergoing treatment for chronic hepatitis C infection, but drinking three or more cups a day also appears to reduce the incidence of hep C treatment side effects by more than 80 percent. If you drink large amounts of coffee while doing treatment with Epclusa it is possible that this may effect treatment outcomes. Relapse is defined as HCV RNA greater than or equal to LLOQ during the post-treatment period after having achieved HCV RNA less than LLOQ at the end of treatment. If you miss a dose, and it is within 18 hours of the missed dose, take it as soon as possible and continue with your regular schedule. Epclusa treats specific genotypes of hepatitis C, and only in certain people. Subjects were randomized in a 1:1 ratio to the treatment groups. If you have ever had hepatitis B, the hepatitis B virus could become active again during and after treatment with EPCLUSA. Epclusa is used to treat chronic hepatitis C in adults and children 6 years of age and older or weighing at least 17kg (37 lbs). No dosage adjustment of Epclusa is warranted in geriatric patients No dosage adjustment of Epclusa is recommended for patients with mild, moderate, or severe renal impairment, including ESRD requiring dialysis No dosage adjustment of Epclusa is recommended for patients with mild, moderate, or severe hepatic impairment (Child-Pugh Class A, B, or C) Clinical and hepatic laboratory monitoring (including direct bilirubin), as clinically indicated, is recommended for patients with decompensated cirrhosis receiving treatment with Epclusa and ribavirin No specific antidote is available for overdose with Epclusa. Don’t know where to start? Available for Android and iOS devices. NS5A resistance-associated substitutions observed with administration of other NS5A inhibitors have been found to persist for longer than 1 year in most patients. Administer Epclusa with or without ribavirin according to the recommendations in Table 1 Adverse Reactions in Subjects without Cirrhosis or with Compensated CirrhosisAdverse Reactions in Subjects Coinfected with HCV and HIV-1Adverse Reactions in Subjects with Decompensated CirrhosisLess Common Adverse Reactions Reported in Clinical TrialsAdverse Reactions in Adult Liver Transplant RecipientsAdverse Reactions in Adults with Severe Renal Impairment Requiring DialysisAdverse Reactions in Pediatric Subjects 6 Years of Age and OlderStudies in Subjects without Cirrhosis and Subjects with Compensated CirrhosisEffect of Baseline HCV Polymorphisms on Treatment ResponseStudies in Subjects without Cirrhosis and Subjects with Compensated CirrhosisGenotype 1, 2, 4, 5, and 6 HCV Infected Adults (ASTRAL-1)Risk of Hepatitis B Virus Reactivation in Patients Coinfected with HCV and HBVSerious Symptomatic Bradycardia When Coadministered with AmiodaroneImportant: If you take Epclusa with ribavirin, you should also read the Medication Guide for ribavirin.For more information about side effects, see the section "Before taking Epclusa, tell your healthcare provider about all of your medical conditions, including if you:Males and females who take Epclusa in combination with ribavirin should also read the ribavirin Medication Guide for important pregnancy, contraception, and infertility information.Tell your healthcare provider about all of the medicines you take,Keep a list of your medicines to show your healthcare provider and pharmacist.Do not start taking a new medicine without telling your healthcare provider.Keep Epclusa and all medicines out of the reach of children.General information about the safe and effective use of EpclusaWe comply with the HONcode standard for trustworthy health information - Among HCV genotype 3 infected subjects with the Y93H polymorphism who were treated with Epclusa for 12 weeks, 7% (2/28) of subjects without cirrhosis relapsed, and 40% (6/15) of subjects with compensated cirrhosis experienced virologic failure (5 relapse, 1 on-treatment).SVR12 was achieved in all 77 subjects who had baseline NS5B nucleoside analog inhibitor resistance polymorphisms including N142T, L159F, E/N237G, C/M289L/I, L320F/I/V, V321A/I, and S282G + V321I. An M289L substitution developed along with the S282T substitution in genotype 2a, 5, and 6 replicons. Serum HCV RNA values were measured during the clinical trials using the COBAS AmpliPrep/COBAS Taqman HCV test (version 2.0) with a lower limit of quantification (LLOQ) of 15 IU/mL.